TherapeuticsMD, Inc.
TXMD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000025743
No open-market purchases or sales by TherapeuticsMD, Inc. insiders were filed in the last 90 days; 44 institutions reported holding it in 13F filings for Q2 2026, worth $9.10M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −4 vs. previous quarter
- 44
- 13F valueReported value at the end of Q2 2026
- $9.10M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding TXMD, Q2 2026
No superinvestor reported holding TXMD at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by TherapeuticsMD, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 29, 2025 (view filing) | Dec 23 | 6 days | Thompson Tommy GDirector | PPurchase | +8.40K | $1.67 | +$14.0K | +56.8%23.2K after | |
| Apr 15, 2025 (view filing) | Apr 14 | 1 day | Thompson Tommy GDirector | PPurchase | +325 | $1.00 | +$325 | +2.2%14.8K after | |
| Apr 15, 2025 (view filing) | Apr 14 | 1 day | Walker Marlan DChief Executive Officer | PPurchase | +490 | $1.00 | +$490 | +0.7%73.6K after | |
| Apr 10, 2025 (view filing) | Apr 9-10 | 1 day | Walker Marlan DChief Executive Officer | PPurchase | +2.30K | $0.8649 | +$1.99K | +3.3%73.1K after | 2 lots |
| Aug 26, 2024 (view filing) | Aug 22 | 4 days | Collins Cooper C.Director | PPurchase | +4.09K | $1.73 | +$7.08K | +8.5%52.0K after | |
| Aug 23, 2024 (view filing) | Aug 21 | 2 days | Collins Cooper C.Director | PPurchase | +1.20K | $1.70 | +$2.04K | +2.6%47.9K after | |
| Dec 7, 2023 (view filing) | Dec 6-7 | 1 day | Walker Marlan DChief Executive Officer | SSale | −19.1K | $2.29 | −$43.7K | −23.3%62.6K after | 2 lots |
| May 4, 2023 (view filing) | Apr 26 | 8 days | Walker Marlan DChief Executive Officer | SSale | −692 | $3.64 | −$2.52K | −5.6%11.6K after | Amended |
| Jan 30, 2023 (view filing) | Jan 26-27 | 4 days | Donegan Michael CPrin. Fin. and Acctg. Officer | SSale | −1.70K | $5.08 | −$8.62K | −12.5%11.9K after | 2 lots |
| Jan 25, 2023 (view filing) | Jan 23-24 | 2 days | Donegan Michael CPrin. Fin. and Acctg. Officer | SSale | −1.31K | $5.34 | −$6.99K | −14.7%7.61K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in TherapeuticsMD, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Rubric Capital Management LP | 1,192,191 | $2.63M | 0.02% | 00.0% | Unchanged |
| Clearline Capital LP | 635,222 | $1.40M | 0.09% | 00.0% | Unchanged |
| Banque Cantonale Vaudoise | 7 | $1.00M | 0.00% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 353,697 | $781.7K | 0.00% | 00.0% | Unchanged |
| Tejara Capital Ltd | 344,482 | $761.3K | 0.31% | −1,370−0.4% | Reduced |
| ADAR1 Capital Management, LLC | 342,447 | $756.8K | 0.04% | +133,237+63.7% | Added |
| Renaissance Technologies LLC | 146,599 | $324.0K | 0.00% | +399+0.3% | Added |
| Morgan Stanley | 129,217 | $285.6K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 115,145 | $254.5K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 105,849 | $234.0K | 0.00% | −3,968−3.6% | Reduced |